Report cover image

Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Oct 31, 2022
Length 124 Pages
SKU # GMD17555254

Description

Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Drugs In Development, 2022, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 11, 12, 1, 17, 10 and 1 respectively.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

124 Pages
Introduction
Global Markets Direct Report Coverage
Axial Spondyloarthritis – Overview
Axial Spondyloarthritis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Axial Spondyloarthritis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Axial Spondyloarthritis – Companies Involved in Therapeutics Development
3SBio Inc
AbbVie Inc
Akeso Inc
AstraZeneca Plc
Avesthagen Ltd
Beijing Eastern Biotech Co Ltd
Bio-Thera Solutions Ltd
Biocad
Biogen Inc
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celltrion Inc
Clover Biopharmaceuticals Ltd
DNX Biopharmaceuticals Inc
Dyadic International Inc
Eli Lilly and Co
Enzene Biosciences Ltd
Foshan Rexie Biotechnology Co Ltd
FunPep Co Ltd
Genrix (Shanghai) Biopharmaceutical Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Hualan Biological Engineering Inc
Iltoo Pharma
Immunwork Inc
Izana Bioscience Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Lynk Pharmaceutical Hangzhou Co Ltd
Mabpharm Ltd
MoonLake Immunotherapeutics
Mycenax Biotech Inc
NeuClone Pty Ltd
Nimbus Therapeutics LLC
North China Pharmaceutical Group New Drug Research and Development Co Ltd
Novartis AG
Outlook Therapeutics Inc
Pharmapraxis
PKU V-Ming (Hefei) Biologics Co Ltd
Qilu Pharmaceutical Co Ltd
Sandoz International GmbH
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Siam Bioscience Co Ltd
SinoCelltech Group Ltd
siRNAgen Therapeutics Corp
Suzhou Zelgen Biopharmaceutical Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
UCB SA
Valin Technologies Ltd
Wuhan Institute of Biological Products Co Ltd
XinThera Inc
Zhejiang Yatai Pharmaceutical Co Ltd
Axial Spondyloarthritis – Drug Profiles
adalimumab biosimilar – Drug Profile
aldesleukin – Drug Profile
Antisense RNAi Oligonucleotides for Autoimmune Disorders – Drug Profile
BCD-180 – Drug Profile
BI-730357 – Drug Profile
bimekizumab – Drug Profile
brodalumab – Drug Profile
CC-99677 – Drug Profile
celecoxib – Drug Profile
certolizumab pegol biosimilar – Drug Profile
CNTO-6785 – Drug Profile
DNX-114 – Drug Profile
DNX-514 – Drug Profile
etanercept biosimilar – Drug Profile
FPP-003 – Drug Profile
golimumab biosimilar – Drug Profile
GR-1501 – Drug Profile
gumokimab – Drug Profile
HB-0017 – Drug Profile
Hemay-005 – Drug Profile
infliximab biosimilar – Drug Profile
ivarmacitinib sulfate – Drug Profile
ixekizumab – Drug Profile
jaktinib hydrochloride – Drug Profile
JS-005 – Drug Profile
KFPH-018 – Drug Profile
LNK-01001 – Drug Profile
LQ-026 – Drug Profile
LZM-012 – Drug Profile
MK2 Backup – Drug Profile
Monoclonal Antibody to Inhibit TNF alpha for Ankylosing Spondylitis, Psoriasis and Rheumatoid Arthritis – Drug Profile
namilumab – Drug Profile
NDI-031407 – Drug Profile
netakimab – Drug Profile
Proteins for Immunology and Metabolic Disorders – Drug Profile
QX-002N – Drug Profile
SCT-650A – Drug Profile
secukinumab – Drug Profile
secukinumab biosimilar – Drug Profile
sonelokimab – Drug Profile
SSGJ-608 – Drug Profile
TE-2122 – Drug Profile
TE-2158 – Drug Profile
upadacitinib ER – Drug Profile
ustekinumab biosimilar – Drug Profile
Van-301 – Drug Profile
vunakizumab – Drug Profile
XIN-005404 – Drug Profile
Axial Spondyloarthritis – Dormant Projects
Axial Spondyloarthritis – Discontinued Products
Axial Spondyloarthritis – Product Development Milestones
Featured News & Press Releases
Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults
Aug 08, 2022: Lilly's Taltz (ixekizumab) now available in new, citrate-free formulation to reduce injection site pain for improved patient experience
Jul 29, 2022: RINVOQ (upadacitinib) approved by European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis
Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the National Medical Products Administration of China
Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
Jul 20, 2022: Health Canada approves AbbVie's RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis
Jun 27, 2022: CHMP recommends approval of Upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis
Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
May 23, 2022: First presentations of phase 3 data for Bimekizumab across the full spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
May 02, 2022: FDA grants approval for AbbVie's Rinvoq to treat ankylosing spondylitis
Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada
Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial
Jan 18, 2022: Positive top-line results for bimekizumab in phase 3 non-radiographic axial spondyloarthritis study
Jan 07, 2022: AbbVie submits applications for Upadacitinib (RINVOQ) in non-radiographic axial spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Axial Spondyloarthritis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Companies, 2022 (Contd..2)
Table 8: Products under Development by Companies, 2022 (Contd..3)
Table 9: Products under Development by Companies, 2022 (Contd..4)
Table 10: Number of Products by Stage and Target, 2022
Table 11: Number of Products by Stage and Mechanism of Action, 2022
Table 12: Number of Products by Stage and Route of Administration, 2022
Table 13: Number of Products by Stage and Molecule Type, 2022
Table 14: Axial Spondyloarthritis – Pipeline by 3SBio Inc, 2022
Table 15: Axial Spondyloarthritis – Pipeline by AbbVie Inc, 2022
Table 16: Axial Spondyloarthritis – Pipeline by Akeso Inc, 2022
Table 17: Axial Spondyloarthritis – Pipeline by AstraZeneca Plc, 2022
Table 18: Axial Spondyloarthritis – Pipeline by Avesthagen Ltd, 2022
Table 19: Axial Spondyloarthritis – Pipeline by Beijing Eastern Biotech Co Ltd, 2022
Table 20: Axial Spondyloarthritis – Pipeline by Bio-Thera Solutions Ltd, 2022
Table 21: Axial Spondyloarthritis – Pipeline by Biocad, 2022
Table 22: Axial Spondyloarthritis – Pipeline by Biogen Inc, 2022
Table 23: Axial Spondyloarthritis – Pipeline by Bioviz Technologies Pvt Ltd, 2022
Table 24: Axial Spondyloarthritis – Pipeline by BioXpress Therapeutics SA, 2022
Table 25: Axial Spondyloarthritis – Pipeline by Boehringer Ingelheim International GmbH, 2022
Table 26: Axial Spondyloarthritis – Pipeline by Bristol-Myers Squibb Co, 2022
Table 27: Axial Spondyloarthritis – Pipeline by Celltrion Inc, 2022
Table 28: Axial Spondyloarthritis – Pipeline by Clover Biopharmaceuticals Ltd, 2022
Table 29: Axial Spondyloarthritis – Pipeline by DNX Biopharmaceuticals Inc, 2022
Table 30: Axial Spondyloarthritis – Pipeline by Dyadic International Inc, 2022
Table 31: Axial Spondyloarthritis – Pipeline by Eli Lilly and Co, 2022
Table 32: Axial Spondyloarthritis – Pipeline by Enzene Biosciences Ltd, 2022
Table 33: Axial Spondyloarthritis – Pipeline by Foshan Rexie Biotechnology Co Ltd, 2022
Table 34: Axial Spondyloarthritis – Pipeline by FunPep Co Ltd, 2022
Table 35: Axial Spondyloarthritis – Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022
Table 36: Axial Spondyloarthritis – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
Table 37: Axial Spondyloarthritis – Pipeline by Hualan Biological Engineering Inc, 2022
Table 38: Axial Spondyloarthritis – Pipeline by Iltoo Pharma, 2022
Table 39: Axial Spondyloarthritis – Pipeline by Immunwork Inc, 2022
Table 40: Axial Spondyloarthritis – Pipeline by Izana Bioscience Ltd, 2022
Table 41: Axial Spondyloarthritis – Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
Table 42: Axial Spondyloarthritis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Table 43: Axial Spondyloarthritis – Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022
Table 44: Axial Spondyloarthritis – Pipeline by Johnson & Johnson, 2022
Table 45: Axial Spondyloarthritis – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Table 46: Axial Spondyloarthritis – Pipeline by Luye Pharma Group Ltd, 2022
Table 47: Axial Spondyloarthritis – Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022
Table 48: Axial Spondyloarthritis – Pipeline by Mabpharm Ltd, 2022
Table 49: Axial Spondyloarthritis – Pipeline by MoonLake Immunotherapeutics, 2022
Table 50: Axial Spondyloarthritis – Pipeline by Mycenax Biotech Inc, 2022
Table 51: Axial Spondyloarthritis – Pipeline by NeuClone Pty Ltd, 2022
Table 52: Axial Spondyloarthritis – Pipeline by Nimbus Therapeutics LLC, 2022
Table 53: Axial Spondyloarthritis – Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, 2022
Table 54: Axial Spondyloarthritis – Pipeline by Novartis AG, 2022
Table 55: Axial Spondyloarthritis – Pipeline by Outlook Therapeutics Inc, 2022
Table 56: Axial Spondyloarthritis – Pipeline by Pharmapraxis, 2022
Table 57: Axial Spondyloarthritis – Pipeline by PKU V-Ming (Hefei) Biologics Co Ltd, 2022
Table 58: Axial Spondyloarthritis – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Table 59: Axial Spondyloarthritis – Pipeline by Sandoz International GmbH, 2022
Table 60: Axial Spondyloarthritis – Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
Table 61: Axial Spondyloarthritis – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Table 62: Axial Spondyloarthritis – Pipeline by Shanghai Novamab Biopharmaceuticals Co Ltd, 2022
Table 63: Axial Spondyloarthritis – Pipeline by Siam Bioscience Co Ltd, 2022
Table 64: Axial Spondyloarthritis – Pipeline by SinoCelltech Group Ltd, 2022
Table 65: Axial Spondyloarthritis – Pipeline by siRNAgen Therapeutics Corp, 2022
Table 66: Axial Spondyloarthritis – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Table 67: Axial Spondyloarthritis – Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022
Table 68: Axial Spondyloarthritis – Pipeline by UCB SA, 2022
Table 69: Axial Spondyloarthritis – Pipeline by Valin Technologies Ltd, 2022
Table 70: Axial Spondyloarthritis – Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
Table 71: Axial Spondyloarthritis – Pipeline by XinThera Inc, 2022
Table 72: Axial Spondyloarthritis – Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
Table 73: Axial Spondyloarthritis – Dormant Projects, 2022
Table 74: Axial Spondyloarthritis – Dormant Projects, 2022 (Contd..1)
Table 75: Axial Spondyloarthritis – Dormant Projects, 2022 (Contd..2)
Table 76: Axial Spondyloarthritis – Dormant Projects, 2022 (Contd..3)
Table 77: Axial Spondyloarthritis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Axial Spondyloarthritis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us